MedDataX Logo

Docosahexaenoic Acid (DHA) Supplementation During Pregnancy Reduces the Risk of Preterm Birth in Threatened Preterm Labor

NCT ID: NCT06302023

Last Updated: 2024-12-12

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-04-01

Study Completion Date

2024-10-07

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this clinical trial is to learn about the effects of Docosahexaenoic acid (DHA) in reducing the incidence of premature birth in threatened preterm labor

The main questions it aims to answer are:

* Can DHA supplementation reduce the incidence of premature birth in threatened preterm labor?
* How does DHA supplementation affect pregnancy outcomes? Participants were organized into two groups
* Group 1 (Intervention) Participants will be asked to take a DHA 1000mg per day
* Group 2 (control) Participant will not need to take a DHA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Threatened preterm labor is defined as regular uterine contractions occurring before 37 completed weeks of gestation, without any cervical dilation.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pregnant Women Diagnosed With Threatened Preterm Labor

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

DHA threatened preterm labor Docosahexaenoic acid

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

DHA supplement

DHA supplement 1000mg per day

Group Type EXPERIMENTAL

Docosahexaenoic acid (DHA) 1000 mg

Intervention Type DIETARY_SUPPLEMENT

Pregnant women will be ask to take a DHA 1000 mg per days at bedtime until delivery or 37 week of gestational age

no DHA supplement

no DHA supplement

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Docosahexaenoic acid (DHA) 1000 mg

Pregnant women will be ask to take a DHA 1000 mg per days at bedtime until delivery or 37 week of gestational age

Intervention Type DIETARY_SUPPLEMENT

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

NOW

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Singleton pregnancy
* Between 24 wk to 34 wk of gestational age
* Pregnant women diagnosed threatened preterm labor (with no cervical change)

Exclusion Criteria

* Fetal anomalies
* Multiple pregnancy
* Premature rupture of membrane
* Placental disorders: placenta previa, placental abruption
* Fetal growth restriction
* Pregnancy complication: gestational diabetes mellitus, Chronic hypertension
* Allergic reaction to DHA
Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Khon Kaen University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Wiphawi Phattharachindanuwong

Fellow, Maternal and Fetal medicine department, Obstetrics and gynecology department

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

KhonKaenU

Khon Kaen, KhonKaen, Thailand

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Thailand

References

Explore related publications, articles, or registry entries linked to this study.

Phattharachindanuwong W, Chaiyarach S, Komwilaisak R, Saksiriwuttho P, Duangkum C, Kongwattanakul K, Kleebkaow P, Waidee T, Pongsamakthai M, Chantanavilai S, Srisataporn T. Docosahexaenoic acid (DHA) Supplementation During Pregnancy Reduces the Risk of Preterm Birth in Threatened Preterm Labor. The Multicenter Randomized Controlled Trial. Int J Womens Health. 2025 Mar 30;17:937-945. doi: 10.2147/IJWH.S518312. eCollection 2025.

Reference Type DERIVED
PMID: 40183030 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

HE661462

Identifier Type: -

Identifier Source: org_study_id